These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12183857)

  • 1. A comprehensive approach to target organ damage in hypertensive women.
    Modena MG; Rossi R
    J Hypertens Suppl; 2002 May; 20(2):S66-9. PubMed ID: 12183857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition.
    Rossi R; Nuzzo A; Iaccarino D; Lattanzi A; Origliani G; Monopoli DE; Modena MG
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):446-55. PubMed ID: 21775407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure.
    Cuspidi C; Valerio C; Sala C; Esposito A; Masaidi M; Negri F; Zanchetti A; Mancia G
    Blood Press Monit; 2008 Feb; 13(1):7-13. PubMed ID: 18199918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction.
    Alecrin IN; Aldrighi JM; Caldas MA; Gebara OC; Lopes NH; Ramires JA
    Heart; 2004 Jul; 90(7):777-81. PubMed ID: 15201248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of preclinical target organ damage in hypertesion: left ventricular hypertrophy.
    Rosei EA
    Blood Press; 2003; 12(3):183-4. PubMed ID: 12875482
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertensive heart disease.
    Diamond JA; Phillips RA
    Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
    Rakić D; Rumboldt Z; Bagatin J; Polić S
    Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia.
    Cuspidi C; Valerio C; Sala C; Meani S; Esposito A; Zanchetti A; Mancia G
    Am J Hypertens; 2007 Jun; 20(6):678-85. PubMed ID: 17531928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women.
    Preston RA
    Climacteric; 2007 Feb; 10 Suppl 1():32-41. PubMed ID: 17364596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpectedly high prevalence of target-organ damage in newly diagnosed Nigerians with hypertension.
    Salako BL; Ogah OS; Adebiyi AA; Adedapo KS; Bekibele CO; Oluleye TS; Okpechi I
    Cardiovasc J Afr; 2007; 18(2):77-83. PubMed ID: 17497043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension.
    Czarnecka D; Kawecka-Jaszcz K; Olszanecka A; Dembińska-Kieć A; Malczewska-Malec M; Zdzienicka A; Guevara I
    Med Sci Monit; 2004 Feb; 10(2):CR55-61. PubMed ID: 14737044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nondipping status does not attenuate the conjugated estrogen-induced improvement in aortic stiffness in postmenopausal women with untreated hypertension.
    Tsioufis C; Tzioumis K; Dimitriadis K; Chatzis D; Skiadas I; Michailidis A; Toutouzas P; Kallikazaros I; Stefanadis C
    Am J Hypertens; 2005 May; 18(5 Pt 1):607-11. PubMed ID: 15882542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target organ damage and associated clinical conditions in newly diagnosed hypertensives attending a tertiary health facility.
    Ayodele OE; Alebiosu CO; Akinwusi PO; Akinsola A; Mejiuni A
    Niger J Clin Pract; 2007 Dec; 10(4):319-25. PubMed ID: 18293643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.